U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.
The drug is made by Orexigen Therapeutics, based in La Jolla, California. The Food and Drug Administration said Thursday it is approved for use by people who have a body mass index of 30 or higher, which is the level at which people are considered to be obese. It is also approved for use by people with a BMI of 27 or higher who also have a weight-related medical condition such as diabetes.
Sales of the drugs have been below expectations because of limited insurance coverage and high costs for patients.